GenSight’s Eye Disease Gene Therapy Shows Sustained Vision Improvement

Paris-based GenSight Biologics reported the first set of data from Week 96 of its REVERSE Phase III clinical trial in 11778-ND4 Leber Hereditary Optic Neuropathy (LHON).

The trial evaluated the safety and efficacy of the company’s single intravitreal injection of GS010, a gene therapy, in 37 patients with LHON.